HTA (Health Technology Assessment) is a process to determine the value of medicines, vaccinations, procedures or health technology. The purpose is to help decision-makers make an informed choice in health-related political questions. This includes the question on whether or not the drug/vaccine/procedure should be reimbursed. And this has direct implications for patients!

Our speaker for this webinar will be Karen Facey. Karen is actively involved in HTA processes in Scotland and Wales and part of relevant bodies and faculties. She will be giving an overview on what HTA is and how patients can be involved in the processes.

Her talk will be followed by two patient advocate speakers from the UK and France, Jayne Bressington and Estelle Lecointe-Artzner. Both will be providing insights on the processes and opportunities for patients to be involved in HTA decisions in their countries.

If HTA is a more or less unknown field to you, don’t let the technical terms scare you! As patient advocates, we can have a say and influence political decisions that will or might have major impact on the lives of sarcoma patients!

Join our webinar, learn about HTA, hear about examples from France and UK – and ask any questions you might have:

Understanding Health Technology Assessment
October 4, 2023, 5pm CET / 11am ET

Agenda

• Basic introduction about HTA and 
  what patient involvement & patient evidence can look like
  Karen Facey, HTAi, UK
• HTA processes in the UK and France
  Jayne Bressington, PAWS GIST / GIST Cancer UK & 
  Estelle Lecointe-Artzner, Info Sarcomes, France
• Outlook on HTA harmonization in Europe: 
  Implementation of the HTA regulation in Europe 2025
  Karen Facey
• Q&A and discussion